Pharming sets 2026 AGM and auditor vote
Pharming Group N.V. has scheduled its 2026 Annual General Meeting of Shareholders for Thursday, May 28, 2026 at 14:00 CET at the Corpus Congress Centre in Oegstgeest, the Netherlands, with a live webcast available.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
6-K
Rhea-AI Filing Summary
Pharming Group N.V. has scheduled its 2026 Annual General Meeting of Shareholders for Thursday, May 28, 2026 at 14:00 CET at the Corpus Congress Centre in Oegstgeest, the Netherlands, with a live webcast available.
The agenda includes appointing KPMG N.V. as external auditor for financial years 2026 through 2028, amendments to the remuneration policy for Non-Executive Directors, and renewal of Board authorizations to issue shares (including rights to acquire shares) and to repurchase shares. Meeting materials, including the Notice to Convene, Explanatory Notes, and Proxy, are available on Pharming’s website under Investors/Shareholder Meetings.
Key Figures
AGM date and time: May 28, 2026 at 14:00 CET
Auditor term: Financial years 2026–2028
2 metrics
AGM date and time
May 28, 2026 at 14:00 CET
Scheduled Annual General Meeting of Shareholders
Auditor term
Financial years 2026–2028
Proposed KPMG N.V. external auditor appointment
Key Terms
Annual General Meeting of Shareholders, Remuneration policy, inside information, EU Market Abuse Regulation
4 terms
Remuneration policy financial
"proposals to amend the Remuneration policy for the Board of Directors"
A remuneration policy is a company’s written guide on how it pays executives and senior managers, covering salary, bonuses, stock awards and other benefits. It matters to investors because it shows how pay is linked to long-term performance and risk—like a recipe that determines whether incentives encourage sustainable growth or reward short-term gains—affecting governance, shareholder returns and potential conflicts of interest.
inside information regulatory
"disclosure of information that qualifies, or may have qualified, as inside information"
Information not available to the public that, if known, would likely cause a company’s stock or bonds to rise or fall—for example, undisclosed earnings, deals, product results, or management plans. It matters because trading on that information gives an unfair advantage, can distort market prices, and is typically illegal or subject to strict rules, so investors watch for proper disclosure and compliance to protect fair, transparent markets.
EU Market Abuse Regulation regulatory
"within the meaning of Article 7(1) of the EU Market Abuse Regulation"
A set of EU-wide rules that prevent cheating in financial markets by banning insider trading, market manipulation, and misleading disclosure; it also requires timely public release of key company information so everyone can play on a level field. For investors, it reduces the risk that prices are driven by secret deals or false signals, making markets fairer and more reliable for deciding when to buy or sell — like referees enforcing fair play in a game.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will Pharming Group (PHAR) hold its 2026 Annual General Meeting?
Pharming Group will hold its 2026 Annual General Meeting of Shareholders on Thursday, May 28, 2026, at 14:00 CET. The meeting takes place at the Corpus Congress Centre in Oegstgeest, the Netherlands, and will also be webcast live for remote participants.
What are the main agenda items for Pharming Group’s 2026 AGM?
Key agenda items include appointing KPMG N.V. as external auditor for financial years 2026–2028, amending the Board remuneration policy for Non-Executive Directors, and renewing Board authorizations to issue shares, grant rights to acquire shares, and repurchase shares.
Which external auditor is proposed at Pharming Group’s 2026 AGM?
The AGM agenda includes a proposal to appoint KPMG N.V. as Pharming Group’s external auditor. The proposed appointment would cover the company’s financial years from 2026 through 2028, subject to approval by shareholders at the meeting.
What changes to remuneration are proposed at Pharming Group’s 2026 AGM?
The AGM agenda includes proposals to amend the remuneration policy for the Board of Directors. Specifically, the changes concern the fees to be paid to the Non-Executive Directors, with details provided in the meeting documents available on Pharming’s investor website.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of April 2026
Commission File Number: 001-39822
Pharming Group N.V.
(Exact Name of Registrant as Specified in Its Charter)
Darwinweg 24
2333 CR Leiden
The Netherlands
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., or the Company, dated April 16, 2026.
EXHIBIT INDEX
Exhibit No. | Description | |||||||
99.1 | Pharming Group announces the 2026 Annual General Meeting of Shareholders | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Pharming Group N.V. | |||||||||||
By: | /s/ Fabrice Chouraqui | ||||||||||
Name: | Fabrice Chouraqui | ||||||||||
Title: | CEO | ||||||||||
Date: April 16. 2026
Pharming Group announces the 2026 Annual
General Meeting of Shareholders
General Meeting of Shareholders
Leiden, the Netherlands, April 16, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that the Company’s 2026 Annual General Meeting of Shareholders (the “AGM”) will be held on Thursday May 28, 2026, at 14:00 CET. The Notice to Convene, Explanatory Notes, Proxy and other meeting documents for the AGM can be found on the Company’s website under Investors/Shareholder Meetings.
The agenda of the AGM includes the proposal to appoint KPMG N.V. as the Company’s external auditor for the financial years 2026 through 2028 and the proposals to amend the Remuneration policy for the Board of Directors regarding the fees to be paid to the Non-Executive Directors.
The agenda of the AGM also includes the renewal of the authorizations for the Board of Directors to issue shares (including rights to acquire shares), and to repurchase shares.
The AGM will be held at the Corpus Congress Centre, Willem Einthovenstraat 1, 2342 BH in Oegstgeest, the Netherlands, and will be webcast live.
About Pharming Group N.V.
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a significant proportion of its employees based in the U.S.
For more information, visit www.pharming.com and find us on LinkedIn.
Inside Information
This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
For further public information, contact:
Investor Relations
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com
Media Relations
Global: Saskia Mehring, Corporate Communications Manager
T: +31 6 28 32 60 41
E: media.relations@pharming.com
U.S.: Ethan Metelenis (Precision AQ on behalf of Pharming)
T: +1 (917) 882-9038
Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)
T: +31 6 53 81 64 27